What Happens When Semaglutide Is Stopped? What STEP 4 Showed

The STEP 4 semaglutide withdrawal trial matters because it asked the question most obesity coverage prefers to avoid: not how to start treatment, but what happens when treatment stops. In adults with overweight or obesity who completed a 20-week run-in on semaglutide 2.4 mg, mean weight fell by 10.6% before randomisation. Over the next 48 weeks, those who stayed on semaglutide lost a further 7.9%, whereas those switched to placebo regained 6.9%. [1]

That is the central clinical point. The trial did not show that semaglutide "fails" off treatment. It showed that obesity is usually a chronic, relapsing physiology, and that withdrawing an effective therapy without a serious maintenance plan is an invitation to drift backwards. [1,2]

The trial design

This was a withdrawal design, not a simple efficacy comparison. Everyone first received semaglutide during an open-label run-in. Only those who reached the maintenance dose and completed that phase were randomised to continue semaglutide or switch to placebo, with lifestyle intervention in both arms. [1] That design matters because it resembles real life more closely than a start-from-scratch trial. Many patients do have an initial response. The hard part is what comes next.

What the results showed

Continued treatment maintained and extended weight reduction. Withdrawal led to regain. [1] STEP 4 also showed divergence in waist circumference, systolic blood pressure, and aspects of glycaemic control, which means the issue was not merely cosmetic regain on the scales. It was broader metabolic reversal. [1]

What most articles miss

STEP 4 does not tell you every patient should remain on semaglutide indefinitely. It tells you that stopping without a plan is risky. The people randomised were responders who had already tolerated dose escalation, so the results apply most directly to patients who have done reasonably well on treatment. [1]

It also matters that the withdrawal period still included lifestyle intervention. Regain happened despite that. This is one reason generic advice such as "just keep the habits" is often inadequate. [1]

The trial also says nothing about the best tapering method, because participants were switched to placebo rather than taken through a structured taper-and-maintain protocol. STEP 4 demonstrates the problem far more clearly than it demonstrates the best solution. The real lesson is about appetite biology, satiety signalling, and the return of the old physiology when pharmacological support is removed. [2]

What this means in practice

For anyone considering stopping semaglutide, STEP 4 is foundational. It justifies monitoring after dose reduction, not because stopping is impossible, but because unobserved drift is common. In practice, that means a planned review at the point of dose reduction, then again during the first four to eight weeks after cessation, when appetite and routine often begin to unravel.

When to involve your clinician

Before withdrawal; at the first sign of rapid appetite return; binge-prone eating; rising waist; loss of training tolerance; or blood pressure or glycaemic drift.

When to seek urgent help

Severe or persistent abdominal pain, vomiting with dehydration, symptoms of gallbladder disease, pancreatitis, or hypersensitivity reactions. [2]

Bottom line

STEP 4 did not prove semaglutide is futile unless taken forever. It proved something more useful: maintenance after a good response is the real clinical battleground. Starting is the easy part. Coming off well is the hard part. [1,2]